Adalimumab

[SDL] Adalimumab Biosimilar (Amgevita) Prefilled Autoinjector 40 mg/0.8 mL

[SDL] Adalimumab Biosimilar (Amgevita) Prefilled Syringe 40 mg/0.8 mL, 20 mg/0.4 mL

View legend

01/09/2020 Adalimumab for treating inflammatory conditions

The Ministry of Health’s Drug Advisory Committee has recommended:

Adalimumab biosimilar (Amgevita) 20 mg/0.4 ml prefilled syringe and 40 mg/0.8 ml prefilled autoinjector and syringe for treating the following inflammatory conditions in line with its registered indications in Singapore:

• Adults with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis, ulcerative colitis, Crohn’s disease or hidradenitis suppurativa;

• Adults with non-infectious intermediate, posterior and panuveitis;

• Children aged 2 years or older with chronic non-infectious anterior uveitis or polyarticular juvenile idiopathic arthritis;

• Children aged 4 years or older with severe chronic plaque psoriasis;

• Children aged 6 years or older with moderately to severely active Crohn’s disease or enthesitis-related arthritis; and

• Children aged 12 years or older with moderate to severe hidradenitis suppurativa;

The removal of adalimumab reference biologic (Humira) 40 mg/0.8 ml prefilled autoinjector from the Medication Assistance Fund (MAF) for all indications; and

Not to list new formulations of Humira (20 mg/0.2 ml or 40 mg/0.4 ml prefilled syringe and pen) on SDL or MAF in view of unfavourable cost effectiveness compared with Amgevita at the price proposed by the manufacturer.

Subsidy status

[R] Adalimumab biosimilar (Amgevita) 20 mg/0.4 ml prefilled syringe and 40 mg/0.8 ml prefilled autoinjector and syringe are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications from 1 September 2020. The MAF listing of Humira will cease on 1 March 2021.

[NR] SDL subsidy does not apply to any formulations or strengths of Humira.

View legend

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration